Cancer Research

KRAS
#Cancer research #Clinical trial #KRAS #Protein

Targeting the undruggable protein: What is the potential for KRAS inhibitors? 

Diana Turner explores the latest KRAS breakthroughs and how our understanding of this illusive protein has developed in recent years.  In September 2025, the inaugural Stephenson Global Prize was awarded to Dr Frank McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, for “groundbreaking discoveries that have transformed the fight… Read More

#Cancer Research #Exclusive Content

Cancer research
#Cancer research #Drug discovery #In Focus Report #Oncology

New InFocus eReport: Advances in cancer research

Although the cancer mortality rate has dropped by 34% since its peak in 1991, the incidence continues to increase for many common cancers. This new DDW InFocus eReport, sponsored by Evotec, provides a full understanding of the current market for oncology drug discovery and the areas… Read More

#Cancer Research #News

Cancer research
#Antibody drug conjugate (ADC) #Cancer research #CAR T-cell therapy #KRAS #Radiopharmaceuticals

New tactics against hard-to-treat cancers

It is an exciting time in cancer drug discovery. Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s, according to the American Cancer Society’s 2026 Cancer Statistics.  New modalities, like radiopharmaceuticals, alongside new drug targets, like KRAS mutations, are resulting in therapies that… Read More

#Cancer Research #Exclusive Content

Medical professional examining mammogram
#Breast cancer #Cancer drug targets #Institute of Cancer Research #Oncology

Research suggests new treatment pathway for triple-negative breast cancers

New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC).  The study, published in Genome Medicine and funded by the charity Breast Cancer Now and others, pinpoints important genes that could be targeted by new drugs. Read More

#Cancer Research #Editor's Choice #News

Modern medical science laboratory
#Cancer Research Horizons #Cancer Research UK #Oncology #UCB

Cancer research alliance to advance ‘life-changing’ therapies 

A global initiative is set to leverage oncology expertise to advance a pipeline of novel cancer therapies.  Biopharmaceutical company UCB has announced a new multi-project alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons.   Under the new partnership, Cancer Research UK’s Centre… Read More

#Cancer Research #News

Neuroendocrine tumours
#Clinical trial #Tumour biology

Trial launched to evaluate neuroendocrine tumour vaccine 

A Phase II trial evaluating a treatment for metastatic neuroendocrine tumours (NETs) has been launched.  SurVaxM, a peptide vaccine, has been developed by biotechnology company MimiVax and will be evaluated in a study conducted at Rosewell Park, New York.  The trial will evaluate SurVaxM in combination with temozolomide… Read More

#Cancer Research #News

Scan to diagnose head and neck cancer
#Cancer research #Head and neck cancer #HPV #Protein targets #Ubiquitin-proteasome

What impact could protein stabilisation have for cancer patients?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Anthony Johnson and Matthew Fyfe from Outrun Therapeutics. Outrun is a biotech specialising in protein stabilisation, an approach being applied to treat HPV+ head and… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Brain cancer #Spain #Tumour biology

Study identifies new target in brain metastasis 

A new study into brain metastasis has identified an immune target with translational potential.  The study, conducted by researchers at the Spanish National Cancer Research Centre (CNIO), has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. Read More

#Cancer Research #News

Cancer cells
#Oncology #Phase II trial #Repertoire Immune Medicines #Solid tumours

Repertoire initiates trial of T cell-targeted immune medicine

Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours.   The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational… Read More

#Cancer Research #Editor's Choice #News

Ovarian cancer cells
#MHRA #Ovarian cancer

MHRA approves clinical trial for ovarian cancer therapy 

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovarian cancer.  CryptiVax-1001, developed by biotechnology company Epitopea, is an off-the-shelf mRNA therapeutic vaccine. It is designed to drive targeted immune responses using a set of tumour-specific antigens chosen for broad… Read More

#Cancer Research #News #Regulatory

#Cancer research #Immune response #Tumour biology

Novel therapy could slow tumour growth, results find 

A novel cancer therapy targeting tumour acidity could boost immune response and slow cancer growth, studies show.  Biotechnology company Dyve Biosciences, in collaboration with Moffitt Cancer Center, reported results for a first-of-its-kind investigational therapy applied to the skin, which is designed to work throughout the body to target the tumour microenvironment –… Read More

#Cancer Research #News

Ovarian cancer
#Corcept Therapeutics #Oncology #Ovarian cancer #Phase III trial

Combo treatment new SOC in platinum-resistant ovarian cancer

Corcept Therapeutics has shared final overall survival data from its pivotal Phase III ROSELLA trial of Lifyorli (relacorilant) combined with the chemotherapeutic agent nab-paclitaxel in patients with platinum-resistant ovarian cancer.  The results were shared in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) 2026… Read More

#Cancer Research #News #Trending News

Ovarian cancer cells
#GSK #Oncology #Ovarian cancer #Phase I trial

B7-H4-targeted ADC shows 62% response rate in ovarian cancer

The global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (Mo-Rez) has shown confirmed objective response rates (cORR) of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent or advanced endometrial cancer (EC).  Mocertatug rezetecan is a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. B7-H4… Read More

#Cancer Research #Editor's Choice #News

Cancer tumour
#Coiled Therapeutics #Oncology #Phase I trial #Solid tumours

First-in-class TACC3 inhibitor for solid tumours shows 80% CBR

Coiled Therapeutics has provided an update on its Phase I/II clinical trial evaluating AO-252, a first-in-class TACC3 inhibitor, in patients with advanced solid tumours.  According to the data, the transition to a Twice-Daily (BID) dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate (CBR), a… Read More

#Cancer Research #News

MRI showing glioblastoma
#Brain cancer #Gene therapy #Trogenix

Gene therapy could eradicate tumours in brain cancer 

An innovative gene therapy could achieve complete tumour elimination in brain cancer, data shows.  Biotechnology company Trogenix has announced the publication of breakthrough preclinical data, reporting complete tumour eradication and durable protection in a state-of-the-art aggressive brain cancer model that closely mimics human glioblastoma (GBM).  The results, published in … Read More

#Cancer Research #News